author-photo

Toni K. Choueiri

Harvard University
Brigham and Women's Hospital
Cleveland Clinic

1324

Papers

55447

Citations

Citation Trend

Filter By

Papers (1324) Sort By

Journal Conference Others

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.

2021 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (23)
Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Association of Neutrophil-to-Lymphocyte Ratio With Efficacy of First-Line Avelumab Plus Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.

2021
Show All
- Source
- Cite
- Save
Citations (10)
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

2021 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (0)
The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract S06-02: Disruption to care of patients with thoracic malignancies: A COVID-19 and cancer outcomes study

2021
Show All
- Source
- Cite
- Save
Citations (0)